Lit­tle biotech de­vel­op­ing Genen­tech castoff drug hits hur­dle in glioblas­toma plat­form tri­al

When the Glob­al Coali­tion for Adap­tive Re­search brought the PI3K in­hibitor pax­al­is­ib in­to its plat­form tri­al for glioblas­toma in ear­ly 2021, the drug’s de­vel­op­er — Aus­tralia’s Kazia Ther­a­peu­tics — was up­beat about how suc­cess in the tri­al, dubbed GBM AG­ILE, may speed up the process of find­ing ef­fec­tive ther­a­pies and “pave the way to pro­vid­ing a new treat­ment in this dis­ease.”

But pax­al­is­ib may now be get­ting weed­ed out from that study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER